Literature DB >> 24496994

[Predictive biomarkers for tumor-relevant signaling pathways in molecular pathology].

I Bonzheim1, F Fend.   

Abstract

In the era of personalized medicine, targeted cancer treatments aim to improve therapy and overall survival. Specific therapies are individually customized for patients based on molecular alterations of the neoplastic cells. The pathologist has a central role in the identification and characterization of a variety of molecular markers that can be used to better predict outcome and assess therapeutic success of specific targeted approaches.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24496994     DOI： 10.1007/s00292-013-1798-6

Source DB:  PubMed          Journal:  Pathologe        ISSN： 0172-8113            Impact factor:   1.011


  35 in total

Review 1.  An update on molecular genetics of gastrointestinal stromal tumours.

Authors:  L Tornillo; L M Terracciano
Journal:  J Clin Pathol       Date:  2006-06       Impact factor: 3.411

Review 2.  Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destiny.

Authors:  Kenichi Suda; Hiroshi Mizuuchi; Yoshihiko Maehara; Tetsuya Mitsudomi
Journal:  Cancer Metastasis Rev       Date:  2012-12       Impact factor: 9.264

Review 3.  Anaplastic Lymphoma Kinase: role in specific tumours, and development of small molecule inhibitors for cancer therapy.

Authors:  E Ardini; P Magnaghi; P Orsini; A Galvani; M Menichincheri
Journal:  Cancer Lett       Date:  2010-10-08       Impact factor: 8.679

4.  EGFR and KRAS mutations in lung carcinoma: molecular testing by using cytology specimens.

Authors:  Shahreen Billah; John Stewart; Gregg Staerkel; Su Chen; Yun Gong; Ming Guo
Journal:  Cancer Cytopathol       Date:  2011-03-11       Impact factor: 5.284

Review 5.  The biology and treatment of EML4-ALK non-small cell lung cancer.

Authors:  Takaaki Sasaki; Scott J Rodig; Lucian R Chirieac; Pasi A Jänne
Journal:  Eur J Cancer       Date:  2010-04-24       Impact factor: 9.162

Review 6.  Unraveling the biologic and clinical complexities of HER2.

Authors:  John W Park; Richard M Neve; Janos Szollosi; Christopher C Benz
Journal:  Clin Breast Cancer       Date:  2008-10       Impact factor: 3.225

7.  Cancer genome sequencing--an interim analysis.

Authors:  Edward J Fox; Jesse J Salk; Lawrence A Loeb
Journal:  Cancer Res       Date:  2009-06-09       Impact factor: 12.701

8.  Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

Authors:  Federica Di Nicolantonio; Miriam Martini; Francesca Molinari; Andrea Sartore-Bianchi; Sabrina Arena; Piercarlo Saletti; Sara De Dosso; Luca Mazzucchelli; Milo Frattini; Salvatore Siena; Alberto Bardelli
Journal:  J Clin Oncol       Date:  2008-11-10       Impact factor: 44.544

9.  KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.

Authors:  F Loupakis; A Ruzzo; C Cremolini; B Vincenzi; L Salvatore; D Santini; G Masi; I Stasi; E Canestrari; E Rulli; I Floriani; K Bencardino; N Galluccio; V Catalano; G Tonini; M Magnani; G Fontanini; F Basolo; A Falcone; F Graziano
Journal:  Br J Cancer       Date:  2009-07-14       Impact factor: 7.640

Review 10.  Imatinib treatment for gastrointestinal stromal tumour (GIST).

Authors:  Lisandro F Lopes; Carlos E Bacchi
Journal:  J Cell Mol Med       Date:  2009-11-28       Impact factor: 5.310
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.